GlassScriptPhysician profile
William Sommers
NPI 1740210830
$13,975.67
in general payments reported to CMS, 2019-2025
54 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,539 · 2020: $2,252 · 2021: $2,773 · 2022: $2,903 · 2023: $2,090 · 2024: $221 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,248 · Consulting Fee: $150 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.76 |
| Consulting Fee | $150.00 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,954.54 | 2019-2023 | Tysabri, Vumerity, Avonex |
| Teva Pharmaceuticals USA, INC. | $1,119.84 | 2019-2024 | Austedo Xr, Austedo |
| Abbvie INC. | $1,105.80 | 2019-2023 | Qulipta, Duopa, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $812.92 | 2019-2023 | |
| Amgen INC. | $716.64 | 2019-2023 | Aimovig |
| Jazz Pharmaceuticals INC. | $611.22 | 2019-2023 | Xywav, Epidiolex |
| Ucb, INC. | $523.84 | 2019-2023 | Briviact |
| Lilly USA, LLC | $502.63 | 2019-2023 | Emgality, Reyvow, Amyvid |
| Genentech USA, INC. | $469.72 | 2019-2023 | Ocrevus |
| Alexion Pharmaceuticals, INC. | $367.24 | 2019-2023 | Ultomiris |
| Acadia Pharmaceuticals INC | $295.73 | 2019-2023 | Nuplazid |
| Avanir Pharmaceuticals, INC. | $291.88 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $289.85 | 2020-2021 | |
| Harmony Biosciences LLC | $264.86 | 2020-2023 | Wakix |
| Genzyme Corporation | $260.06 | 2019-2023 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sommers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.